Article date: November 2010
By: Jürgen B. Bulitta, Martina Kinzig, Verena Jakob, Ulrike Holzgrabe, Fritz Sörgel, Nicholas H. G. Holford, in Volume 70, Issue 5, pages 682-693
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
AIMS
(i) To describe the first‐order and mixed‐order elimination pathways of piperacillin, (ii) to determine the between occasion variability (BOV) of pharmacokinetic parameters and (iii) to propose optimized dosage regimens.
METHODS
We performed a five‐period replicate dose study in four healthy volunteers. Each subject received 4 g piperacillin as a single 5 min intravenous infusion in each study period. Drug analysis was performed by HPLC. We used NONMEM and S‐ADAPT for population pharmacokinetic analysis and Monte Carlo simulation to predict the probability of target attainment (PTA) with a target time of non‐protein bound concentration above MIC >50% of the dosing interval.
RESULTS
A model with first‐order nonrenal elimination and parallel first‐order and mixed‐order renal elimination had the best predictive performance. For a 70 kg subject we estimated 4.40 l h−1 for nonrenal clearance, 5.70 l h−1 for first‐order renal clearance, 170 mg h−1 for Vmax, and 49.7 mg l−1 for Km for the mixed‐order renal elimination. The BOV was 39% for Vmax, 117% for Km, and 8.5% for total clearance. A 30 min infusion of 4 g every 6 h achieved robust (≥90%) PTAs for MICs ≤12 mg l−1. As an alternative mode of administration, a 5 h infusion of 6 g every 8 h achieved robust PTAs for MICs ≤48 mg l−1.
CONCLUSIONS
Part of the renal elimination of piperacillin is saturable at clinically used doses. The BOV of total clearance and volume of distribution were low. Prolonged infusions achieved better PTAs compared with shorter infusions at similar daily doses. This benefit was most pronounced for MICs between 12 and 48 mg l−1.
DOI: 10.1111/j.1365-2125.2010.03750.x
View this article